Ophthotech has completed patient recruitment in the second phase 3 trial of Fovista in combination with Lucentis for the treatment of wet age-related macular degeneration, the company announced in a press release. The two phase 3 clinical trials are investigating the superiority of Fovista (pegpleranib, Ophthotech) in combination with Lucentis (ranibizumab, Genentech) over Lucentis monotherapy. Data from the two clinical trials will be analyzed together “to optimize pooled analysis of certain relevant endpoints in accordance with the statistical analysis plan,” the release said.
Uncategorized